Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ #GVHD–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced two oral presentations at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. The presentations include new findings demonstrating durability of clinical response out to one year for patients with high-risk acute graft-v
Click here to view original post